Evommune (EVMN) Current Leases (2024 - 2026)

Evommune's (EVMN) quarterly Current Leases came in at $1.3 million in Q1 2026, up 417.77% on a QoQ basis from $242000.0 in Q4 2025.

Evommune (EVMN) Current Leases (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Current Leases data on file, last reported at $1.3 million in Q1 2026.

On a quarterly basis, Current Leases changed N/A year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $1.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $242000.0, down 50.31% from the prior year.
Current Leases for Q1 2026 stood at $1.3 million, up from $242000.0 in the prior quarter.
Over the last five years, Current Leases for EVMN reached as high as $1.3 million in Q1 2026 and fell as low as $160000.0 in Q3 2025.
Historically, Current Leases has averaged $535500.0 across 3 years, with a median of $364500.0 in 2024.
On a YoY basis, Current Leases climbed as much as 50.31% in 2025 and fell as far as 50.31% in 2025.
Year by year, Current Leases stood at $487000.0 in 2024, then tumbled by 50.31% to $242000.0 in 2025, then soared by 417.77% to $1.3 million in 2026.
Per Business Quant data, the three most recent Current Leases figures were $1.3 million in Q1 2026, $242000.0 in Q4 2025, and $160000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	531,233.95
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	20.58 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	872,589.03
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	720.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	11.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	16.61 Mn
10	Evommune	381.48 Mn	170.02 Mn	-	1.25 Mn

Download Data